Market News Today — AI-Curated Stock & Crypto Headlines

The FDA is considering shifting prescription medications to over-the-counter (OTC) status, starting with non-addictive and non-hazardous drugs, aiming for changes this year.

Eli Lilly is stockpiling its GLP-1 weight loss pills ahead of FDA approval, potentially indicating a positive outcome for the drug's regulatory review.

Moderna's seasonal vaccine development is facing challenges due to the FDA's current review process, which has been deemed 'risky' by an analyst.

The FDA has found Novo Nordisk's TV ad for its obesity pill to contain 'false or misleading' claims, prompting the agency to request immediate action from the company.

Hims & Hers has abandoned its weight-loss drug due to a potential patent infringement issue with Novo Nordisk's Wegovy, following an FDA probe.

The US FDA has announced a crackdown on copycat weight-loss drugs, specifically targeting Hims & Hers, a telehealth company that has undercut Novo Nordisk's obesity shot prices, raising concerns about regulatory compliance and market competition.

The Dow Jones Industrial Average surpassed the 50,000 mark, driven by a rally in chip stocks, particularly Nvidia, AMD, and Broadcom, due to increased spending on AI data centers by Amazon and Alphabet.

Novo Nordisk shares experienced a rally after the FDA chief threatened to block a copycat version of their drug, potentially favoring the Danish drugmaker in a dispute.

The FDA rejected AstraZeneca's subcutaneous version of its lupus medicine, potentially impacting the company's revenue and market share in the lupus treatment market.

Akeso's CFO expresses confidence in the company's cancer drug ivonescimab receiving FDA approval, citing a positive outlook for the regulatory process.

The FDA plans to expedite approvals for generic biologic medicines, a move aimed at reducing high prescription drug costs in the US, potentially impacting pharmaceutical companies negatively.

The article discusses the regulation of functional food claims, highlighting the differences between the US and EU approaches.